MEGAN CARAVAS: Open Payments
NPI 1740875459 · CHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,056 in 149 payments from 20 companies in 2025. Trend: 2023 $2,617 · 2024 $2,069 · 2025 $3,056
Food & beverage: $3,056
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $552 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $477 |
| Janssen Biotech, Inc. | 19 | $370 |
| QOL Medical, LLC | 11 | $314 |
| GENZYME CORPORATION | 7 | $210 |
| Madrigal Pharmaceuticals | 5 | $177 |
| PFIZER INC. | 8 | $163 |
| Ipsen Biopharmaceuticals, Inc | 7 | $158 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $138 |
| Ardelyx, Inc. | 8 | $137 |
Products named: TREMFYA, Sucraid, ENTYVIO, DUPIXENT, EOHILIA, REZDIFFRA, RINVOQ, IQIRVO.
Industry payments across VA — which companies pay providers there.
